JPH0359898B2 - - Google Patents
Info
- Publication number
- JPH0359898B2 JPH0359898B2 JP58022245A JP2224583A JPH0359898B2 JP H0359898 B2 JPH0359898 B2 JP H0359898B2 JP 58022245 A JP58022245 A JP 58022245A JP 2224583 A JP2224583 A JP 2224583A JP H0359898 B2 JPH0359898 B2 JP H0359898B2
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- formula
- oxy
- compound
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 208000032839 leukemia Diseases 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 51
- -1 (methylamino)-carbonyl Chemical group 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000012948 isocyanate Substances 0.000 claims description 14
- 150000002513 isocyanates Chemical class 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 5
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000002844 melting Methods 0.000 description 25
- 230000008018 melting Effects 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- 239000013078 crystal Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- CMYYQTVLUJXQRH-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CNC(=O)N(C(C)=O)OC(=O)NC(C)(C)C CMYYQTVLUJXQRH-UHFFFAOYSA-N 0.000 description 2
- LQDATRANQKTSSQ-UHFFFAOYSA-N [cyclopropanecarbonyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(=O)NCCC)C(=O)C1CC1 LQDATRANQKTSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VIHDBAIWGYSTFR-UHFFFAOYSA-N n-hydroxycyclopropanecarboxamide Chemical compound ONC(=O)C1CC1 VIHDBAIWGYSTFR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- ZQBSJPQCSZLHOG-UHFFFAOYSA-N [2,2-dimethylpropanoyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C(C)(C)C ZQBSJPQCSZLHOG-UHFFFAOYSA-N 0.000 description 1
- GDRBIRLKLBFXDJ-UHFFFAOYSA-N [acetyl(butylcarbamoyl)amino] n-butylcarbamate Chemical compound CCCCNC(=O)ON(C(C)=O)C(=O)NCCCC GDRBIRLKLBFXDJ-UHFFFAOYSA-N 0.000 description 1
- CYWMOWCOOYBYKZ-UHFFFAOYSA-N [acetyl(cyclohexylcarbamoyl)amino] n-cyclohexylcarbamate Chemical compound C1CCCCC1NC(=O)N(C(=O)C)OC(=O)NC1CCCCC1 CYWMOWCOOYBYKZ-UHFFFAOYSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- KFVPSAYXCYQTMK-UHFFFAOYSA-N [acetyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=CC=C1 KFVPSAYXCYQTMK-UHFFFAOYSA-N 0.000 description 1
- FYYNYTLWTNFHAS-UHFFFAOYSA-N [acetyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(C)=O)C(=O)NC(C)C FYYNYTLWTNFHAS-UHFFFAOYSA-N 0.000 description 1
- SDVNEYFNWCZEDS-UHFFFAOYSA-N [acetyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(C)=O)C(=O)NCCC SDVNEYFNWCZEDS-UHFFFAOYSA-N 0.000 description 1
- LSNBVLYXRZAHAC-UHFFFAOYSA-N [acetyl(tert-butylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)N(C(=O)C)OC(=O)NC(C)(C)C LSNBVLYXRZAHAC-UHFFFAOYSA-N 0.000 description 1
- KUUQWZJOSIGJFP-UHFFFAOYSA-N [acetyl-[(3-methylphenyl)carbamoyl]amino] n-(3-methylphenyl)carbamate Chemical compound C=1C=CC(C)=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=CC(C)=C1 KUUQWZJOSIGJFP-UHFFFAOYSA-N 0.000 description 1
- TUZYCYGFIFHVRI-UHFFFAOYSA-N [acetyl-[(4-methylphenyl)carbamoyl]amino] n-(4-methylphenyl)carbamate Chemical compound C=1C=C(C)C=CC=1NC(=O)N(C(=O)C)OC(=O)NC1=CC=C(C)C=C1 TUZYCYGFIFHVRI-UHFFFAOYSA-N 0.000 description 1
- CDEPGIYPAJXMAG-UHFFFAOYSA-N [benzoyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C1=CC=CC=C1 CDEPGIYPAJXMAG-UHFFFAOYSA-N 0.000 description 1
- JEDKOPDVYJICRO-UHFFFAOYSA-N [benzoyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C=1C=CC=CC=1)OC(=O)NC1=CC=CC=C1 JEDKOPDVYJICRO-UHFFFAOYSA-N 0.000 description 1
- BSFZTEHBSPCPTF-UHFFFAOYSA-N [benzoyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(=O)NC(C)C)C(=O)C1=CC=CC=C1 BSFZTEHBSPCPTF-UHFFFAOYSA-N 0.000 description 1
- KZQUDIJFQJZKJM-UHFFFAOYSA-N [benzoyl(propylcarbamoyl)amino] n-propylcarbamate Chemical compound CCCNC(=O)ON(C(=O)NCCC)C(=O)C1=CC=CC=C1 KZQUDIJFQJZKJM-UHFFFAOYSA-N 0.000 description 1
- MBMVEHLDUZXWPP-UHFFFAOYSA-N [benzoyl(tert-butylcarbamoyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)ON(C(=O)NC(C)(C)C)C(=O)C1=CC=CC=C1 MBMVEHLDUZXWPP-UHFFFAOYSA-N 0.000 description 1
- WLBFTDQYYWFOHM-UHFFFAOYSA-N [cyclohexylcarbamoyl(cyclopropanecarbonyl)amino] n-cyclohexylcarbamate Chemical compound C1CCCCC1NC(=O)N(C(=O)C1CC1)OC(=O)NC1CCCCC1 WLBFTDQYYWFOHM-UHFFFAOYSA-N 0.000 description 1
- LZWPPKWORJRBBP-UHFFFAOYSA-N [cyclopropanecarbonyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(=O)NC)C(=O)C1CC1 LZWPPKWORJRBBP-UHFFFAOYSA-N 0.000 description 1
- PLWGXZYSZBUAPR-UHFFFAOYSA-N [cyclopropanecarbonyl(phenylcarbamoyl)amino] n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)N(C(=O)C1CC1)OC(=O)NC1=CC=CC=C1 PLWGXZYSZBUAPR-UHFFFAOYSA-N 0.000 description 1
- GPFXTBLPSNPIHF-UHFFFAOYSA-N [cyclopropanecarbonyl(propan-2-ylcarbamoyl)amino] n-propan-2-ylcarbamate Chemical compound CC(C)NC(=O)ON(C(=O)NC(C)C)C(=O)C1CC1 GPFXTBLPSNPIHF-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- IYEBVKCNBIGUJR-UHFFFAOYSA-N [methylcarbamoyl(propanoyl)amino] n-methylcarbamate Chemical compound CCC(=O)N(C(=O)NC)OC(=O)NC IYEBVKCNBIGUJR-UHFFFAOYSA-N 0.000 description 1
- NWAVDZPATQKPSN-UHFFFAOYSA-N [tert-butylcarbamoyl(cyclopropanecarbonyl)amino] n-tert-butylcarbamate Chemical compound CC(C)(C)NC(=O)ON(C(=O)NC(C)(C)C)C(=O)C1CC1 NWAVDZPATQKPSN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- LDDOSDVZPSGLFZ-UHFFFAOYSA-N ethyl cyclopropanecarboxylate Chemical compound CCOC(=O)C1CC1 LDDOSDVZPSGLFZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ATDOYFPHCIRHKH-UHFFFAOYSA-N n-hydroxy-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NO ATDOYFPHCIRHKH-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Polyamides (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US349502 | 1982-02-17 | ||
| US06/349,502 US4413009A (en) | 1982-02-17 | 1982-02-17 | N-((Alkylamino)carbonyl)-N-(((alkylamino)carbonyl)oxy)acylamides with antineoplastic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58152858A JPS58152858A (ja) | 1983-09-10 |
| JPH0359898B2 true JPH0359898B2 (enExample) | 1991-09-12 |
Family
ID=23372667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58022245A Granted JPS58152858A (ja) | 1982-02-17 | 1983-02-15 | 抗新生物活性を有する，ｎ−（（アルキルアミノ）カルボニル）−ｎ−（（アルキルアミノ）カルボニル）オキシ）アシルアミド類 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4413009A (enExample) |
| EP (1) | EP0086492B1 (enExample) |
| JP (1) | JPS58152858A (enExample) |
| AT (2) | AT387962B (enExample) |
| BE (1) | BE895923A (enExample) |
| CA (1) | CA1196007A (enExample) |
| CH (1) | CH653014A5 (enExample) |
| DE (2) | DE3305107A1 (enExample) |
| FR (1) | FR2521555A1 (enExample) |
| GB (1) | GB2115414B (enExample) |
| IT (1) | IT1199988B (enExample) |
| NL (1) | NL8300598A (enExample) |
| SE (1) | SE8300854L (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100228318B1 (ko) * | 1997-03-14 | 1999-11-01 | 윤종용 | 다중 펄스코드 변조데이터 합성회로 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3786088A (en) * | 1968-12-05 | 1974-01-15 | Velsicol Chemical Corp | N,o-dicarbamoyl-n-phenylhydroxylamines |
| US3836572A (en) * | 1973-04-02 | 1974-09-17 | Monsanto Co | Dicarbamoyl hydroxamates |
| US3957867A (en) * | 1973-04-11 | 1976-05-18 | Hercules Incorporated | Certain oximinyl allophanates and their use as herbicides |
| US4030912A (en) * | 1973-04-11 | 1977-06-21 | Hercules Incorporated | Certain oximinyl allophanates and their use as herbicides |
| US4207091A (en) * | 1976-02-09 | 1980-06-10 | Ciba-Geigy Corporation | Method of preventing plants from damage by frost |
-
1982
- 1982-02-17 US US06/349,502 patent/US4413009A/en not_active Expired - Lifetime
-
1983
- 1983-02-14 CA CA000421553A patent/CA1196007A/en not_active Expired
- 1983-02-14 CH CH811/83A patent/CH653014A5/de not_active IP Right Cessation
- 1983-02-14 AT AT0049483A patent/AT387962B/de not_active IP Right Cessation
- 1983-02-15 DE DE19833305107 patent/DE3305107A1/de not_active Withdrawn
- 1983-02-15 EP EP83101435A patent/EP0086492B1/en not_active Expired
- 1983-02-15 AT AT83101435T patent/ATE22071T1/de not_active IP Right Cessation
- 1983-02-15 JP JP58022245A patent/JPS58152858A/ja active Granted
- 1983-02-15 DE DE8383101435T patent/DE3365949D1/de not_active Expired
- 1983-02-15 GB GB08304146A patent/GB2115414B/en not_active Expired
- 1983-02-16 SE SE8300854A patent/SE8300854L/xx not_active Application Discontinuation
- 1983-02-16 IT IT19608/83A patent/IT1199988B/it active
- 1983-02-16 BE BE0/210127A patent/BE895923A/fr not_active IP Right Cessation
- 1983-02-17 FR FR8302605A patent/FR2521555A1/fr active Granted
- 1983-02-17 NL NL8300598A patent/NL8300598A/nl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2115414B (en) | 1985-09-18 |
| BE895923A (fr) | 1983-08-16 |
| US4413009A (en) | 1983-11-01 |
| IT8319608A1 (it) | 1984-08-16 |
| NL8300598A (nl) | 1983-09-16 |
| EP0086492A3 (en) | 1984-06-06 |
| IT1199988B (it) | 1989-01-05 |
| SE8300854L (sv) | 1983-08-18 |
| CH653014A5 (de) | 1985-12-13 |
| FR2521555A1 (fr) | 1983-08-19 |
| AT387962B (de) | 1989-04-10 |
| DE3305107A1 (de) | 1983-08-18 |
| ATA49483A (de) | 1988-09-15 |
| GB8304146D0 (en) | 1983-03-16 |
| EP0086492B1 (en) | 1986-09-10 |
| SE8300854D0 (sv) | 1983-02-16 |
| ATE22071T1 (de) | 1986-09-15 |
| IT8319608A0 (it) | 1983-02-16 |
| JPS58152858A (ja) | 1983-09-10 |
| DE3365949D1 (en) | 1986-10-16 |
| EP0086492A2 (en) | 1983-08-24 |
| FR2521555B1 (enExample) | 1985-05-17 |
| GB2115414A (en) | 1983-09-07 |
| CA1196007A (en) | 1985-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6583165B2 (en) | Arylsulfonanilide ureas | |
| US3679698A (en) | 2-nitroimidazoles | |
| EP0242851A1 (de) | N-(2'-Aminophenyl)-benzamid-Derivate, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung neoplastischer Erkrankungen | |
| EP0525111B1 (en) | Antiinflammatory hydroxamic acids and n-hydroxyureas | |
| US3665009A (en) | 1-carbamolypyrazole-4-sulfonamides | |
| FR2555049A1 (fr) | Medicaments a base de carboxymethoxy-7 furo-(3,4-c)-pyridine | |
| DE69108408T2 (de) | 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung. | |
| Toro et al. | Cyrhetrenylaniline and new organometallic phenylimines derived from 4-and 5-nitrothiophene: Synthesis, characterization, X-Ray structures, electrochemistry and in vitro anti-T. brucei activity | |
| FR2580642A1 (fr) | 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant | |
| US2945877A (en) | Carbamic acid esters of 2, 4, 5-trichlorophenol | |
| FI61886C (fi) | Foerfarande foer framstaellning av i tumoerterapi anvaendbara 1-alkylkarbamoyl-5-fluoruraciler | |
| DE69402142T2 (de) | Ornithine-decarboxylase hemmende cyclische aminooxy-verbindungen | |
| JPH0359898B2 (enExample) | ||
| US2449638A (en) | Substituted glycinamides | |
| US2829084A (en) | Certain alkyl-n | |
| PL128998B1 (en) | Process for preparing novel 2-amino-3-benzoylphenylacetamides and their derivatives | |
| WO1998031688A1 (fr) | Derives d'acides boroniques inhibiteurs d'angiogenese | |
| GB2024814A (en) | Acyl (bicyclic aryl) - aminoalkanoic acids | |
| Elslager et al. | Synthetic schistosomicides. XVI. 5-(Mono-and dialkylamino)-2-nitrosophenols, 2-amino-5-(dialkylamino) phenols, and related compounds | |
| US3929803A (en) | Aryl carboxylic acids | |
| JPH01165586A (ja) | 抗腫瘍プロドラッグ | |
| US3299089A (en) | Derivatives of 5-methyloxazoline and 5-chloromethyloxazoline | |
| AU685980B2 (en) | Inhibition of leukotriene biosynthesis with urea derivatives | |
| SU782337A1 (ru) | 2Н,4Н-2,4-диметил-6-амино-1,3,5 дитиазин, обладающий радиозащитным действием | |
| US2947743A (en) | N4-aminoacetyl-, n4-lower alkylaminoacetyl- and n4-di-lower alkylamino-acetyl-6-sulfanilamido-2, 4-dimethoxypyrimidines |